Cyclin D1 is probably the most extensively studied cyclin in breast tumors, and its overexpression has been reported in more than 50% of breast cancer cases, as detected in TNBC and hormone-independent HER2+ [224,225]. This evidence concerns the gene ERBB2 and breast carcinoma.